INTRODUCTION
The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole are established adjuvant therapies for postmenopausal women with early-stage breast cancer. This is based on multiple large, randomized clinical trials that have been conducted in the initial therapy setting 1, 2 after 2 to 3 years of tamoxifen [3] [4] [5] [6] and in the extended adjuvant therapy setting after about 5 years of tamoxifen. 7, 8 An American Society of Clinical Oncology (ASCO) panel concluded that optimal adjuvant therapy for postmenopausal women with receptorpositive breast cancer includes an AI, either as initial therapy or after treatment with tamoxifen. 9 However, a substantial proportion of women are suboptimally adherent to anastrozole therapy, 10 and about half of patients treated with AIs have joint-related complaints, 11, 12 which likely contributes to decreased compliance.
MA.27 is a phase III trial comparing the nonsteroidal AI anastrozole with the steroidal AI exemestane as adjuvant therapy for early breast cancer. Musculoskeletal complaints were the most frequent
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reason given by patients on this trial for discontinuing therapy. We used a genome-wide association study (GWAS) 13 to identify any SNP (single nucleotide polymorphism) associated with musculoskeletal adverse events (MS-AEs) in women receiving AI adjuvant therapy for early breast cancer, followed by studies of the possible functional basis for the associations.
PATIENTS AND METHODS

Source of Patients
Cases and controls were obtained from the MA.27 trial conducted by the NCIC Clinical Trials Group (coordinating group), Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group (ECOG), North Central Cancer Treatment Group, Southwest Oncology Group, and International Breast Cancer Study Group (IBCSG). MA.27 included postmenopausal women with completely resected stages I to III breast cancer (American Joint Committee on Cancer [AJCC] Version 6) that was estrogen receptor (ER) positive and/or progesterone receptor positive. Patients were randomly assigned to 5 years of anastrozole or exemestane. This research was performed after approval by local institutional review boards in accordance with assurances filed with and approved by the Department of Health and Human Services.
Accrual of 6,827 North American patients occurred between May 2003 and July 2008, with the majority providing DNA and consent for genetic testing. Non-North American patients (n ϭ 693) entered by the IBCSG did not contribute DNA. MA.27 initially included a second random assignment to celecoxib or placebo, but this was discontinued in December 2004 after the entry of 1,622 patients because of reports of cardiovascular toxicity associated with celecoxib.
14
Case Definition for MS-AEs
Cases had at least one of the following six MS-AEs: joint pain, muscle pain, bone pain, arthritis, diminished joint function, or other musculoskeletal problems. Cases were required to either (1) have at least grade 3 toxicity, according to the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events v3.0, or (2) go off treatment for any grade of MS-AE within the first 2 years (ie, an MS-AE occurring after 2 years was not considered a case). Participants who fulfilled the case definition while on celecoxib or within 3 months after stopping celecoxib were excluded as cases.
Control Definition
Controls did not experience any of the MS-AEs, were followed for at least 2 years, and had at least 6 months longer follow-up than a case to which they were matched. This meant that all controls were off celecoxib for at least 6 months.
Study Design
A nested, matched case-control design was used, with matching on the following factors: treatment arm (exemestane, anastrozole), prior adjuvant chemotherapy (yes, no), age at start of AI treatment (Ϯ 5 years), celecoxib (yes, no), and time on study. When possible, each case was matched exactly with two controls. Otherwise, we used close matching based on a distance between each case and all potential controls determined with an optimal matching algorithm. 15 The majority of MA.27 patients were white (94%), and this GWAS was restricted to white patients. Additional covariates evaluated were body mass index, bisphosphonate use (yes, no), fractures in past 10 years (yes, no), baseline ECOG performance status, prior hormone replacement therapy (HRT; yes, no), prior adjuvant radiotherapy (yes, no), and prior taxane (yes, no).
Genotyping and Quality Control
Two cases and two controls were randomly chosen as duplicates for quality control of genotype concordance. A white parent-child Centre d'Etude du Polymorphisme Humain (CEPH) trio from the HapMaP was included to check for Mendelian transmission of alleles. Genotypes were determined by the RIKEN Center for Genomic Medicine with the Illumina Human610-Quad BeadChip platform (Illumina, San Diego, CA).
Statistical Analyses
Primary analyses were based on conditional logistic regression to account for the matched design. SNP genotypes were coded as additive effects on the log odds ratio by coding as 0, 1, or 2 for the count of the minor allele. This resulted in a likelihood ratio test with 1 df for each SNP. The primary covariates used to match cases and controls were implicitly controlled in conditional logistic regression.
To avoid biases that might arise from differences in genetic ancestry (ie, population stratification), EIGENSTRAT software was used to determine eigenvalues for the SNP correlation matrix that statistically differed from zero on the basis of Tracy-Widom P values. 16, 17 The corresponding eigenvectors were used as covariates in logistic regression models. We performed additional analyses to evaluate the robustness of our findings that are described in the Appendix (online only). Statistical analyses were conducted with the R statistical computing package, and SAS (SAS Institute, Cary, NC) and PLINK software.
18
Imputation and Fine Mapping
SNPs were imputed within 300 kb on either side of the region containing the three SNPs with smallest P values on chromosome 14 using MACH 1.0 software, 19 with the white CEPH European Ancestry (CEU) as the reference panel. A region (Ϯ 200 kb) around these same three SNPs was fine mapped at the RIKEN Center for Genomic Medicine. First, 29 SNPs were genotyped that were registered in the HapMaP database. After considering linkage disequilibrium (LD) among the SNPs, the strongest associated region of 20 kb (range, 95.23 to 95.25 Mb) was resequenced in 94 samples using an ABI3730 Genetic Analyzer (Applied Biosystems, Carlsbad, CA). From the 119 SNPs that were identified by resequencing, 16 additional SNPs with a minor allele frequency of 0.05 or more were genotyped using multiplex polymerase chain reactionbased Invader assay.
Functional Genomic Studies
The three genotyped SNPs on chromosome 14 with the smallest P values, as well as an imputed SNP with a small P value that was validated by fine mapping, were studied functionally using electrophoretic motility shift (EMS) assays, chromatin immunoprecipitation (ChIP) assays, determination of their relationship to TCLIA expression after estrogen exposure, and transfection studies. Details of the methods used to perform these functional assays are described in the Appendix.
RESULTS
Cases and Controls
This analysis involved 293 cases and 585 controls which, including the duplicate samples and CEPH trios, had call rates of 0.982 to 0.999. Additional details are provided in the Appendix.
Patient Characteristics
Table 1 data show that the cases and controls were well balanced for most factors except prior HRT, which was significantly higher in cases (66% v 44%; P Ͻ .001), and fractures within the past 10 years, which was also slightly higher in cases (13% v 9%; P ϭ .06).
MS-AEs
The maximum grade MS-AEs are presented in Table 1 according to whether the patients discontinued AI therapy. Among the 293 cases, the number of days until the first MS-AE ranged from 10 to 726 (median, 223 days; mean, 276 days). The majority of cases had joint pain as their only MS-AE (184 cases; 62.8%) or in combination with other MS-AEs (56 cases; 19.1%).
Genotyping Results
In all, 592,236 SNPs were genotyped, but 11,281 (1.9%) were considered failures by the laboratory. Of these, 29,478 SNPs with a minor allele frequency (MAF) Ͻ 0.01 were excluded because of limited power for association analyses. The exact test for Hardy-Weinberg equilibrium was performed in the controls. The quantile-quantile plot of these P values (Appendix Fig A1, online only) illustrates SNPs with a departure from Hardy-Weinberg equilibrium, and we excluded 82 SNPs with a P value Ͻ 1E-06; sensitivity analyses were conducted with differing P value thresholds, and they did not affect the analysis (data not shown). Therefore 551,395 SNPs were used for the association analyses.
Control for Potential Population Stratification
To control for potential population stratification, SNPs were chosen that were uncorrelated with each other to avoid local genomic LD having undesirable impact on global genomic estimates of population stratification. SNPs were considered uncorrelated when the absolute value of the Pearson correlation was Ͻ 0.063. [20] [21] [22] This resulted in 7,077 SNPs being used in the EIGENSTRAT analyses. From these analyses, eight eigenvalues were identified with Tracy-Widom P values Ͻ .05. None of the corresponding eight eigenvectors differed significantly (ie, all P Ͼ .05) between cases and controls.
GWAS Analyses: Cases Versus Controls
By the conditional logistic regression analyses adjusted for population stratification, the smallest P value was 7.74E-07, close to the commonly accepted threshold for genome-wide significance of 1E-07. Adjusting for the eigenvectors had little influence on the results (see quantile-quantile plot for the conditional logistic regression results, both adjusted and unadjusted for the eigenvectors, in Appendix Fig  A2, online only) , which also illustrates that the variation inflation factor lambda in Devlin and Roeder 23 is close to 1.0. The distribution of P values across the genome is illustrated in the Manhattan plot (Fig 1A) . The most striking P values (Ͻ 1E-06) were for three SNPs on chromosome 14 (Table 2) . Adjusting for the eight eigenvectors, or additionally for prior history of fractures and HRT use, did not substantially alter our findings, nor did the results change substantially according to the unadjusted and unmatched Armitage P values (Table 2) . Exploratory analyses for possible SNP-SNP interactions and per allele differences between the two blinded treatment arms were all nonsignificant after adjusting for multiple testing.
Imputation and Fine Mapping
Imputing SNPs within 300 kb of the smallest P value SNPs on chromosome 14, illustrated in Figure 1B , showed that rs7159713 and rs2369049 were in LD with rs7158782 (Pearson correlation of minor allele dosage Ͼ 0.8) and that an additional imputed SNP (rs11849538) also showed an association with MS-AEs (MAF cases/controls: 0.172/ 0.091; odds ratio, 2.21; P ϭ 6.67E-07). Using the imputed data, we focused on a 200-kb region and genotyped 29 SNPs, including the imputed SNP (rs11849538), which was verified by this genotyping and the DNA sequencing. We examined the LD block of the candidate region and focused on the strongest associated region of 20 kb (95.23 to 95.25 Mb), which included four SNPs (rs7158782, rs7159713, rs2369049, and rs11849538). We resequenced this region and identified a total of 119 SNPs that included 49 novel SNPs and 70 SNPs already registered in the dbSNP database. Hence, we genotyped 16 additional SNPs with MAFs of 0.05 or greater, but no SNP showed a stronger association than rs11849538. Therefore, we concluded that rs11849538 or the other three highly linked SNPs (rs7158782, rs7159713, and rs2369049) might have functional significance.
Functional Genomic Studies of SNPs on Chromosome 14
The three genotyped SNPs (rs7158782, rs7159713, and rs2369049) and the imputed SNP (rs11849538) were all close to the T-cell leukemia 1A (TCL1A) gene (Fig 2) . All four of these SNPs were in LD (R 2 Ͼ 0.85). We attempted to determine whether any of these SNPs might be functional on the basis of EMS or ChIP assays, and if they were, whether they might be associated with variation in the expression of the closest gene, TCL1A; whether estrogens might play a role in their functional effects; and, finally, whether TCL1A might influence the expression of receptors or cytokines known to play a role in arthritis.
We first determined that TCL1A is highly and variably expressed in 288 lymphoblastoid cell lines from three different ethnic groups for which we have expression array data as well as genome-wide SNP data. EMS assays performed with lymphoblastoid cell nuclear extract showed a shift (ie, protein binding) for all but the rs2369049 SNP, with less binding by the variant than by the wild type (WT) sequences in all 
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www.jco.org cases (Appendix Figs 3A to 3C, online only). The TRANSFAC database predicted that rs7158782 would disrupt a GATA-1 binding motif, and this prediction was supported by a ChIP assay (Appendix Fig 3C) . However, of particular importance for this study, the TRANSFAC database also predicted that the SNP closest to the 3Ј end of TCL1A-rs11849538 -would create an estrogen response element (ERE), and this prediction was supported by the results of a ChIP assay (Fig 3C) performed using ER␣-transfected lymphoblastoid cells with known genotype for the rs11849538 SNP. We then determined whether TCL1A expression might be estrogen dependent by exposing U20S cells stably transfected with ER␣ or ER␤ to 0.1 nmol/L 17-␤-estradiol (E2) and found eight-and six-fold increases in TCL1A mRNA expression after 18 hours and 1 hour, respectively (Figs 3A and 3B), linking TCL1A expression to estrogens.
We then determined the effect of different genotypes at these four SNPs on the estrogen-dependent TCL1A expression. To do that, we transiently transfected lymphoblastoid cell lines with known genotypes for the four SNPs with ER␣, exposed the cell lines to various concentrations of E2, and determined the relationship of the SNPs to TCL1A expression (Fig 3D) . In all three ethnic groups, the cells with the variant sequences-sequences that created an ERE at rs11849538 -showed greater TCL1A expression than did those with the WT sequence.
Finally, we knew that interleukin 17 (IL17) and the IL17 receptor A (IL17RA) were both therapeutic targets in patients with rheumatoid arthritis, 24 so we determined whether the expression of TCL1A was correlated with the expression of either IL17 or IL17RA in the same 288 lymphoblastoid cell lines. Expression of TCL1A and IL7RA were correlated (r ϭ 0.36; P Ͻ 1.9E-10). We then demonstrated in U2OS cells that small interfering RNA knockdown of TCL1A resulted in decreased expression of IL17RA but increased expression of IL17 mRNA ( Figs 4A and 4B ), while overexpression of TCL1A resulted in increased IL17RA expression and decreased expression of mRNA for the ligand IL17 ( Figs 4C and 4D) .
DISCUSSION
This genome-wide nested case-control study identified four SNPs in tight LD on chromosome 14 that were associated with MS-AEs in women receiving AIs for resected early-stage breast cancer, with P values that ranged from 2.23E-06 to 6.67E-07, close to the Bonferroni threshold of 1E-07. The closest gene to these SNPs was TCL1A, with 
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The significant advantages of our study design are that it avoids selection biases and exposure recall biases among cases, maximizes representativeness of controls, optimizes measurement of exposure (randomized treatment allocation), and ensures unbiased follow-up of all participants in a protocol-specified manner. In fact, our study design can be viewed as being strong as a cohort study but much more efficient. 25 There are, however, general limitations of all GWASs, 26 including the potential for false-positive associations, that underscore the requirement for replication. There were imbalances between cases and controls in terms of HRT and prior fractures, but these did not confound our findings. We recognize that the NCI criteria used to measure MS-AEs can be somewhat subjective, possibly with heterogeneous causes that could reduce power, but this does not have an impact on our findings. Additionally, our functional genomic studies are sufficiently compelling to justify further research. The purpose of this study was both to identify genetic markers for MS-AEs and to explore mechanisms that might be related to this drug-related AE in women exposed to AI-dependent decreased estrogen levels. Therefore, we examined functional characteristics of the SNPs as they might relate to estrogen action. It was striking that the SNP with the smallest P value (rs11849538) created an ERE shown by ChIP assay to be functional (Fig 3C) . We determined whether estrogens and/or the SNPs might be functionally related to TCL1A, and we demonstrated an eight-fold induction of TCL1A expression by 24 hours in ER␣-transfected cells (Fig 3A) and significantly higher TCL1A expression after exposure to varying concentrations of E2 in lymphoblastoid cell lines containing the variant SNPs when compared with cells having the WT sequence after transient transfection with ER␣ ( Fig 3D) .
TCL1A expression has previously been associated with a number of hematopoietic malignancies, including T-cell and B-cell lymphomas, 27 and has been shown to enhance Akt serine threonine kinase activity, thus functioning as an Akt coactivator. 28 TCL1A expression is thought to be restricted to early developmental cells of the immune system, including CD4 Ϫ , CD8 Ϫ , and CD3 Ϫ thymocytes. 28 However, there were no previous reports of the regulation of TCL1A by estrogen or of an association of TCL1A expression with cytokine receptor expression. Patients who carry the SNP variant identified in our GWAS that creates an ERE (rs11849538) might be more responsive to a given level of estrogen and thus display higher levels of TCL1A expression for any given level of estrogen (Fig 3D) . A reduction in estrogen levels during AI therapy might result in proportionally greater reductions in TCL1A expression in women with these SNPs than in women with the WT sequence. The mechanism by which differential changes in TCL1A expression might induce MS-AEs remains to be determined, but our observations with regard to its relationship to IL17RA expression indicate that the association of TCL1A expression with cytokine function is worthy of further exploration in the course of future studies. Finally, it is intriguing to speculate that our findings in women receiving AIs who develop MS-AEs may provide insight into the "arthritis of the menopause" described by Cecil and Archer 85 years ago.
29 AI therapy might be considered an estrogen-deprivation stress test that could provide novel insights into symptoms related to estrogen deprivation that occur during menopause-74% of women without breast cancer in the Women's Health Initiative clinical trials reported joint pain. 30 In summary, this GWAS identified four SNPs on chromosome 14 that were related to MS-AEs in patients receiving AI adjuvant therapy. The combination of four strong SNP signals and the equally strong functional linkage of these SNPs to AI effect focused our attention on these polymorphisms as possible biomarkers for risk for this important adverse drug reaction, on TCL1A as the potential link, and on cytokines as potential mechanistic factors. The determination of the mechanism of these MS-AEs would enable a focused approach to amelioration of symptoms, thus facilitating compliance and improving the benefits of AIs for women with early breast cancer.
